Practice managers, physicians, and members of industry gathered recently at the Cancer Center Business Summit (CCBS) to consider the state of cancer care delivery and its future. A panel discussion among key thought leaders featured perspectives from the oncology community as well as national policy advisors.
I was disturbed recently after reading a news report in which the head of a large pharmacy benefit manager (PBM) stated the company’s intentions to eventually start influencing the price of oncology drugs as well as extend its management, oversight, and influence to cancer drugs administered in doctors’ offices and hospitals. Meetings have already begun with top oncologists, according to the company leader who was interviewed, and the company is looking to find ways to eventually guide doctors toward preferred drugs in the PBM’s approved formulary in ways that do not cause patients to be upset.
Oncology Practice Management recently conducted the following interview with Lillie D. Shockney, RN, BS, MAS, Administrative Director, The Johns Hopkins Breast Center; Director, Cancer Survivorship Programs at the Sidney Kimmel Cancer Center at Johns Hopkins; and Associate Professor, Johns Hopkins University School of Medicine and School of Nursing, Baltimore, MD. Ms Shockney is also a cancer survivor and the editor-in-chief of the Journal of Oncology Navigation & Survivorship.
Changes in oncology payment and reimbursement as well as delivery models were reviewed recently by an expert panel at the Cancer Center Business Summit (CCBS). Providers, payers, industry representatives, and thought leaders were on hand to share their thoughts and experiences.
The US Food and Drug Administration (FDA) is hoping that its December 4, 2014, final rule on pregnancy and breastfeeding labeling for prescription drugs and biological products1 will be helpful to patients and providers. Clinicians are also optimistic about the changes but are waiting to see whether sufficient data will be available to truly clarify the risks of using each medication during conception, pregnancy, and lactation.
San Francisco, CA—The rising costs of biomolecular testing and targeted drugs have prompted many to ask whether the United States can afford personalized medicine in oncology. At the Third Annual PMO Live Conference, a Global Biomarkers Consortium Initiative, medical directors from 2 health plans tackled this question from the payer perspective.
Section 529 College Savings plans are tax-advantaged college savings vehicles, and one of the most popular ways to save for college today. Known officially as “qualified tuition programs,” 529 college savings plans have changed the world of tuition savings, much like the way 401(k) plans changed the world of retirement savings a few decades ago. While a 529 plan may be the best vehicle to save for college, you will need to understand the basics in order to make the right choice.
- Radiation Therapy With or Without Androgen Deprivation Therapy
- Safety and Efficacy of Enzalutamide
- DCVAC Added to Standard Chemotherapy
- Enzalutamide and Mifepristone
- Enzalutamide plus Dutasteride as First-Line Treatment
- Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate
- Calcitriol, Ketoconazole, and Hydrocortisone
- Metformin Prostate Cancer Adjuvant Trial
- Enzalutamide plus Leuprolide
- Jakafi Gets New Indication for Use in Patients with Polycythemia Vera
- Cyramza Approved in Combination with Docetaxel for Metastatic NSCLC
- Blincyto First Immunotherapy Approved for B-Cell Acute Lymphoblastic Leukemia
- Avastin plus Chemotherapy for Platinum-Resistant Gynecologic Cancers
- FDA Approves Nivolumab for Advanced Melanoma
Nivolumab (Opdivo): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma
Although less common than other skin cancers, melanoma is the most dangerous form of skin cancer. According to data collected between 2004 and 2010, the 5-year relative survival rate for Americans with distant melanoma is only 16% for all ages, races, and sexes. The National Cancer Institute estimated that there were 76,100 new cases of skin melanoma in 2014, and more than 9700 patients died from this disease during the same period.
FDA-Approved Medications Used for the Treatment of Renal Cell Carcinoma
Results 1 - 11 of 11